Filing Details
- Accession Number:
- 0001209191-19-041297
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-07-03 20:00:20
- Reporting Period:
- 2019-07-02
- Accepted Time:
- 2019-07-03 20:00:20
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
897448 | Amarin Corp Plc | AMRN | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1770259 | Aaron Berg | C/O Amarin Pharma, Inc. 1430 Route 206 Bedminster NJ 07921 | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Ordinary Shares | Acquisiton | 2019-07-02 | 69,564 | $2.50 | 105,915 | No | 4 | M | Direct | |
Ordinary Shares | Disposition | 2019-07-02 | 50,000 | $20.46 | 55,915 | No | 4 | S | Direct | |
Ordinary Shares | Disposition | 2019-07-02 | 19,564 | $21.42 | 36,351 | No | 4 | S | Direct | |
Ordinary Shares | Acquisiton | 2019-07-03 | 29,250 | $2.80 | 65,601 | No | 4 | M | Direct | |
Ordinary Shares | Disposition | 2019-07-03 | 29,250 | $22.64 | 36,351 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Ordinary Shares | Stock Option (Right to Buy) | Disposition | 2019-07-02 | 69,564 | $0.00 | 69,564 | $2.50 |
Ordinary Shares | Stock Option (Right to Buy) | Disposition | 2019-07-03 | 29,250 | $0.00 | 29,250 | $2.80 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
49,998 | 2025-07-06 | No | 4 | M | Direct | |
87,750 | 2028-05-01 | No | 4 | M | Direct |
Footnotes
- The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- Please see the section title "Remarks" below for additional information.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.32 to $20.675, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.62 to $22.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- On July 6, 2015, the Reporting Person was granted an option to purchase 400,000 Ordinary Shares under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). The shares subject to this option shall vest and become exercisable in 48 equal monthly installments on the last day of each month that began on July 31, 2015.
- On May 1, 2018, the Reporting Person was granted an option to purchase 117,000 Ordinary Shares under the Plan. The shares subject to this option shall vest as follows: 25% of the total number of underlying shares shall vest on May 1, 2019, and the remaining 75% of the underlying shares shall vest ratably over the subsequent 36 months.